With an unprecedented number of new investigational agents and companies in immuno-oncology (IO), it has been difficult to track and understand the current IO agents in clinical development and the clinical trials testing these agents. The Clinical Accelerator team presents an unbiased, neutral, scientifically curated, and timely updated analysis based on information collected from numerous trusted and publicly available sources.
We hope to inform the cancer research community through academic publications as it strives for efficiencies and innovation while avoiding duplication. As of today, we have two landscape publications: a comprehensive IO landscape analysis (Annals of Oncology, December 2017) and a global landscape of cancer cell therapy (Nature Reviews Drug Discovery, May 2018). Subscribe to our email newsletter to receive the latest updates on our landscape analyses.
A global landscape of cancer cell therapies. 753 cancer cell therapies are included in the interactive dashboard. The top graph serves as the filter to curate the following two graphs and one table. Seven different classes of cell therapies are defined based on their mechanism of actions. More details and other analyses can be found in the Nature Reviews Drug Discovery article
The overview of 2,004 IO agents. 6 classes of IO agents are identified on the basis of different mechanisms of actions. Unspecified tumor associated antigen (Unspecified TAA) is defined as the target of unspecified antigens from either individual patients or cell lines. In this sense, therapies against this target mainly consist of cell line-based vaccines, autologous tumor vaccines, autologous DC vaccines, and tumor infiltrating T cell therapies (TIL). Personalization is defined as the targets discovered by algorithm-based approaches from, e.g., the individual patients’ tumor samples or blood circulating DNA. More details can be found in the Annals of Oncology article
Timeline of Anti-PD-1/L1 Antibody Approvals by the FDA.